Compare Davita Inc (DVA) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Procter & Gamble Co — how do they compare? Davita Inc trades at $180.95 (market cap $11.72B), while Procter & Gamble Co trades at $144.9 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 29× Davita Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PG | |
|---|---|---|
Market Cap | $11.72B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $167.18 |
52-Week Low | $103.87 | $138.10 |
Enterprise Value | $24.44B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Procter & Gamble (PG) trades at $144.77, down 0.69% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company maintains strong fundamentals with $84.28B revenue, 18.44% net margin, and consistent dividend payments, though valuation multiples remain elevated versus peers. Recent news highlights institutional positioning shifts and the company's new WNBA partnership.
PG offers stable cash flows and dividend growth potential but faces premium valuation concerns and modest revenue growth outlook. Near-term catalysts include Q3 2026 earnings, while risks include competitive pressures and economic sensitivity. Analyst consensus remains positive with a $161.20 price target suggesting 11% upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
